Search the Newsreel

Form 8K Theravance Biopharma Inc For: 10 August By Investing.com

This article announces that Theravance Biopharma Inc. filed a Form 8K on August 10, 2026. The filing is a standard SEC disclosure for significant corporate events. The brief note from Investing.com provides no further details about the content of the 8K.

Theravance's Once-Daily COPD Treatment Posts $70.7M Sales

Theravance Bio: Q2 Earnings Snapshot

Theravance Biopharma Inc. (TBPH) reported a second-quarter loss of $5.9 million, or 11 cents per share. Adjusted earnings were 19 cents per share, while the company's revenue of $20.7 million surpassed analyst expectations of $19.8 million. This financial snapshot highlights their performance in the …

Brava Energia (BRAV3) rescinde acordo de acionistas em meio à mudança de controle para a Ecopetrol

Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical company specializing in the production of proprietary enzymes and devices. …

CAVA Stock Is Flat in 2026, It Reached $95 and Gave It All Back. Here’s Why.

CAVA Group stock is flat in 2026, having twice reached $95 and then fallen back to $62 despite strong revenue growth. The stock's stagnation is attributed to a management outlook that signaled deceleration and large holders selling shares at the $90 peak. While analysts …

Theravance Biopharma (TBPH) Earnings Date and Reports 2026

Is Avient (AVNT) Still Below Fair Value After Strong Earnings And Raised Guidance?

Avadh Sugar & Energy Ltd. Share Price Near 52-Week High

Avarga (SGX:X5N) Stock Rebounds To Profit As One Off Loss Clouds Outlook

Avista (AVA) Earnings Growth And Dividend Keep Fair Value In Focus

Chenavari Toro Income Fund Limited EUR Revenue Breakdown – LSE:TORG

Savara Extends MOLBREEVI Patent Protection to 2041

Savara Inc. has secured patent protection in Europe and Australia for its investigational lung-disease therapy, MOLBREEVI, extending coverage to March 2041. These patents cover the liquid formulation and add to existing protection for the drug-device combination, strengthening the company's intellectual property portfolio in markets …

Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Avantor, Inc. (NYSE:AVTR) on behalf of shareholders who purchased securities prior to March 5, 2024, and continue to hold them. The investigation focuses on whether Avantor and its officers engaged in corporate wrongdoing. The …

Sei Investments Co. Purchases 92,063 Shares of Avanos Medical, Inc. $AVNS

Avista Corp (AVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Securities Lawsuit Alert: Avantor, Inc. (AVTR) Investors - Contact Levi & Korsinsky Before December 29, 2025

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Avantor, Inc. (NYSE:AVTR) on behalf of investors who purchased securities between March 5, 2024, and October 28, 2025. The lawsuit alleges that Avantor made false statements regarding its competitive position, increased competition, …

ROSEN, LEADING INVESTOR COUNSEL, Encourages Datavault AI Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DVLT

NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Datavault AI Inc. (NASDAQ: DVLT) between September 4, 2024 and October 30, 2025, inclusive …

Lost Money on Avantor, Inc. (AVTR)? Join Class Action Before December 29, 2025 - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Avantor, Inc. (NYSE: AVTR) on behalf of investors who purchased securities between March 5, 2024, and October 28, 2025. The lawsuit alleges that Avantor made false statements regarding its competitive position and …

Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX

Renaissance Technologies LLC has acquired a new position in Novavax, Inc. (NASDAQ:NVAX), purchasing 497,383 shares valued at approximately $4.05 million. This investment represents a 0.30% stake in Novavax, which recently reported better-than-expected Q2 earnings, though revenue fell significantly year-over-year. The biopharmaceutical company has a …

CAVA Group Stock Rallies After-Hours On FY26 Expectations Match, Q4 Earnings Beat

Endava PLC (2Y5.DU) Stock Price, News, Quote & History

The article provides a snapshot of Endava PLC (2Y5.DU) stock information, including its current price, market performance, and historical data. As of the latest update, the stock was trading at 2.5800 EUR, down 0.39%. The performance overview shows significant negative returns across YTD, 1-Year, …

Did Stronger Q2 Profitability and a Steady Dividend Just Shift Avista's (AVA) Investment Narrative?

Avista Corp. reported stronger second-quarter 2026 profitability with a rise in net income to US$35 million and basic EPS to US$0.43, alongside maintaining its routine quarterly dividend of US$0.4925 per share. This improved financial performance supports the income-oriented investment thesis for the regulated utility, …

Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)

Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Avalo Therapeutics (AVTX) with a price target of $35.00. This comes despite the company reporting a wider GAAP net loss of $36.36 million in its latest quarterly earnings compared to the previous …

Avista Begins Safety-Focused Vegetation Management Following Wildfires

Avista is initiating safety-focused vegetation management in wildfire-affected areas to remove fire-damaged trees and vegetation that pose a risk to power lines, utility equipment, and public safety. This effort, starting August 8th, aims to enhance safety for residents, first responders, and utility crews during …

Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed

In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …

Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Savara Inc. (NASDAQ:SVRA) during the first quarter, purchasing an additional 320,572 shares to own a total of 652,672 shares valued at approximately $3.56 million. Other institutional investors also modified their holdings, with hedge funds and institutions …

Avalanche Treasury Gets Nasdaq Delisting Warning Over Minimum Bid Price and Market Value Compliance

Avalanche Treasury Corporation (AVAT) has received two deficiency notices from Nasdaq, warning of potential delisting due to its failure to meet the minimum bid price and market value of listed securities requirements. The company's stock price has been below $1.00 for 33 consecutive business …

Form 8K Avalanche Treasury Corp For: 7 August By Investing.com

The article reports that Avalanche Treasury Corp filed a Form 8K on August 7th. It includes general market data and related news headlines, but no specific details from the Form 8K filing are provided. The content focuses on market performance, commodity prices, and other …

Avalanche Treasury Ord Shs Class A (AVAT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Avalanche Treasury Ord Shs Class A (AVAT), focusing on future EPS and revenue growth estimates. It includes a snapshot of the stock's current market performance, key financial metrics, and a peer comparison with other companies in the …

Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week High - Time to Buy?

Avalyn Pharma (NASDAQ:AVLN) recently hit a new 52-week high of $33.49, closing at $32.93, with a market capitalization of $1.47 billion. Analysts maintain a "Buy" rating with a consensus price target of $59, despite the company reporting a quarterly EPS loss that missed expectations. …

Navan stock may move 12% on Aug. 14 earnings report By Investing.com

Navan Inc. Class A shares are projected to move 12% when the company releases its earnings on August 14, according to options data. Historically, Navan's stock has exceeded the implied move in one of its last three earnings announcements, jumping 42.5% against a 9.3% …

CAVA Group, Inc. $CAVA Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in CAVA Group, Inc. by 37.6% in the first quarter, selling 781,634 shares but still retaining 1.30 million shares valued at approximately $105.0 million. Institutional investors collectively own 73.15% of the company's stock. CAVA Group reported …

Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP

CAVA Group, Inc. (NYSE:CAVA) Given Average Rating of "Moderate Buy" by Brokerages

CAVA Group, Inc. (NYSE:CAVA) has received an average rating of "Moderate Buy" from 28 brokerages, with an average 12-month price target of $92.46. The company recently reported strong quarterly earnings, beating estimates with $0.20 EPS and a 32.1% year-over-year revenue increase to $438.27 million. …